Natus Medical Adds to Its Neurodiagnostic Service Market
March 09 2016 - 7:46PM
Natus Medical Incorporated (NASDAQ:BABY) today announced that it
has expanded its neurodiagnostic services into seven new states
with the acquisition of the assets of NeuroQuest, LLC, a provider
of neurodiagnostic services.
"The addition of NeuroQuest further strengthens our
Global Neurodiagnostic ("GND") brand as a leading provider in our
rapidly growing ambulatory EEG service business," said Jim Hawkins,
President and Chief Executive Officer. "GND's organic growth
combined with this acquisition offer an exciting opportunity for
Natus and our customers as we expand the service throughout the
United States." Hawkins continued.
"We expect this acquisition to add approximately
$2.5 million in additional revenue during 2016 and to be
immediately accretive to earnings," said Hawkins.
GND offers patients and physicians a more
convenient way to complete ambulatory video EEG testing which can
be performed at the home, hospital or physician's office. The
service also provides comprehensive reporting and support to the
physician.
About Natus Medical
Natus is a leading provider of healthcare products
and services used in the screening, detection, treatment,
monitoring and tracking of common medical ailments in newborn care,
hearing impairment, neurological dysfunction, epilepsy, sleep
disorders, and balance and mobility disorders.
Additional information about Natus Medical can be
found at www.natus.com.
Forward Looking Statements
This press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, particularly statements regarding the expectations,
beliefs, plans, intentions and strategies of Natus. These
forward-looking statements include statements regarding historical
revenue and profitability of GND the anticipated expansion of the
GND services. These statements relate to current estimates and
assumptions of our management as of the date of this press release,
and future events or Natus' future financial performance or
results, and involve known and unknown risks, uncertainties and
other factors that may cause actual results, levels of activity,
performance, or achievements to differ materially from those
expressed or implied by the forward-looking statements.
Forward-looking statements are only predictions and the actual
events or results may differ materially. Natus cannot provide any
assurance that its future results or the results implied by the
forward-looking statements will meet expectations. Our future
results could differ materially due to a number of factors,
including the effects of competition, the demand for our products
and services, the impact of adverse global economic conditions on
our target markets, our ability to expand our sales in
international markets, our ability to maintain current sales levels
in a mature domestic market, our ability to control costs, risks
associated with bringing new products to market and integrating
acquired businesses, and our ability to fulfill product orders on a
timely basis. Natus disclaims any obligation to update information
contained in any forward looking statement.
More information about potential risk factors
that could affect the business and financial results of Natus is
included in Natus' annual report on Form 10-K for the year ended
December 31, 2015, and its subsequent quarterly reports on Form
10-Q, and in other reports filed from time to time by Natus with
the U.S. Securities and Exchange Commission.
COMPANY CONTACT:
Natus Medical Incorporated
Jonathan A. Kennedy
Sr. Vice President Finance and Chief Financial Officer
(925) 223-6700
InvestorRelations@Natus.com
PishPosh (NASDAQ:BABY)
Historical Stock Chart
From Jun 2024 to Jul 2024
PishPosh (NASDAQ:BABY)
Historical Stock Chart
From Jul 2023 to Jul 2024